TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02612610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant administered as one 7.5 mg, 20 mg, or 50 mg tablet twice daily, depending upon randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant administered as one 7.5 mg, 20 mg, or 50 mg tablet twice daily, depending upon randomization.
Study: NCT00796614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin hydrochloride
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin hydrochloride
Description: Oral
Study: NCT02612610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant administered as one 7.5 mg, 20 mg, or 50 mg tablet twice daily, depending upon randomization.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for gefapixant)
Study: NCT00554541

Intervention type: OTHER
Intervention: Ankle Brachial Index Venous physiologic study
Description: Assessment of lower extremity venous disease

Intervention type: OTHER
Intervention: Ankle Brachial Index Venous physiologic study
Description: Assessment of lower extremity venous disease

Intervention type: OTHER
Intervention: Ankle Brachial Index Venous physiologic study
Description: Assessment of lower extremity venous disease
Study: NCT00796614

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT00049335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 1,000 mg/m\^2/dose (2,000 mg/m\^2/day) BID, PO, on Days 1-14 of 21 day cycle
Study: NCT03955354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1210
Description: SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib mesylate
Description: apatinib Mesylate is a small molecule tyrosine kinase inhibitor,Through selectively inhibiting the tyrosine kinase activity of the vascular endothelial growth factor receptor 2 (VEGFR-2).
Study: NCT02946307

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restore DEB（dimeter>2.00 mm）

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute DES

Intervention type: DEVICE
Group type: OTHER
Intervention: Restore DEB（dimeter:2.00 mm）
Study: NCT02580968

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electro-acupuncture
Description: electro-acupuncture on acupoints according to the traditional syndrome diagnosis.once per day, for 20 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: flunarizine hydrochloride
Description: flunarizine hydrochloride ，10mg/day，for 20 days。
Study: NCT02073721

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrostimulation with exercises MAPs
Description: this group will make the electrostimulation with exercises of the pelvic floor muscles with a focus on strengthening the pelvic floor muscles.the frequency will be 20 sessions, 2 times per week, lasting 30 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercises MAPs
Description: This group will focus exercises of the pelvic floor muscles with strengthening the muscles of the pelvic floor. the frequency will be 20 sessions, 2 times per week, lasting 30 minutes.
Study: NCT04316520

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: Ketogenic diet 2:1
Study: NCT03511378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lupin's Pegfilgrastim
Description: Administration of Pegfilgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neulasta®
Description: Administration of Neulasta®
Study: NCT01101464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine 3x5mg followed by 1x15mg
Description: Three 5 mg sublingual tablets (15 mg) given twice daily for 2 days followed by one 15 mg sublingual tablet given twice daily for 1.5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine 1x15mg followed by 3x5mg
Description: One 15 mg sublingual tablet given twice daily for 2 days followed by three 5 mg sublingual tablets (15 mg) given twice daily for 1.5 days.
Study: NCT04103086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: Free aromatherapy (70% menthol and 30% propanediol) will be provided for 6 months. All participants will receive the standard inhalation method training before hospital discharge.~The aromatherapy will be given twice daily, one treatment in the morning and one in the evening. At each treatment, 4 deep steady inhalations will be performed, and 10 seconds per inhalation is optimal.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Free placebo (10% menthol and 90% propanediol) will be provided for 6 months. The specific method is the same as aromatherapy
Study: NCT02652390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 80 mg
Description: 2 mL methylprednisolone (40 mg/mL) + 1 mL lidocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 40 mg
Description: 1 mL methylprednisolone (40 mg/mL) + 1 mL saline + 1 mL lidocaine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 2 mL saline + 1 mL lidocaine
Study: NCT03867552

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Altered gas (86% CO2, 10% N2O, 4% O2)
Description: Assessment of pain degree after laparoscopic surgery with the altered gas (86% CO2, 10% N2O, 4% O2)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standardized gas (100% CO2)
Description: Assessement of pain degree after laparoscopic surgery with the standardized gas (100% CO2)
Study: NCT00560313

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Men ACWY CRM
Description: A single dose of a 0.5 mL injectable solution

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4CMenB
Description: All subjects received the study vaccine following a 0,2,6 vaccination schedule. Pre-filled syringe, administered by intramuscular injection into the deltoid area of the non dominant arm.
Study: NCT01231464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone furoate nasal spray
Description: fluticasone furoate nasal spray 110ug, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT00344253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Study: NCT03449134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants receive dose-matched placebo tablets orally BID during the 12-week main study period and during the 40-week extension period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants receive dose-matched placebo tablets orally BID during the 12-week main study period and during the 40-week extension period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants receive dose-matched placebo tablets orally BID during the 12-week main study period and during the 40-week extension period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant 15 mg or 45 mg tablet administered orally BID during the 12-week main study period and during the 40-week extension period, according to randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant 15 mg or 45 mg tablet administered orally BID during the 12-week main study period and during the 40-week extension period, according to randomization.
Study: NCT01410084

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 100,000 IU vitamin D3 once monthly for 5 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin E
Description: 400 IU vitamin E once monthly for 5 months
Study: NCT00993798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SABER-Bupivacaine Treatment 1a
Description: 5.0 ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SABER-Bupivacaine Treatment 1b
Description: 5.0 ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl Treatment 1c
Description: 20.0 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SABER-Bupivacaine Treatment 2a
Description: 7.5 ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SABER-Bupivacaine Treatment 2b
Description: 7.5 ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl Treatment 2c
Description: 20.0 ml
Study: NCT00383630

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intramyocardial injection of bone marrow mononuclear cells
Description: 6mL of bone marrow mononuclear cells will be injected into the myocardium during LVAD implantation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intramyocardial injection of CD34+ selected bone marrow mononuclear cells
Description: 6mL of CD34+ selected bone marrow mononuclear cells will be injected into the myocardium during LVAD implantation.

Intervention type: DEVICE
Group type: OTHER
Intervention: LVAD alone
Description: LVAD implantation without any intramyocardial injection of bone marrow cells.
Study: NCT00887198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: 1000 mg per day (4 x 250-mg tablets) taken orally.
Study: NCT03027206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibration technique
Description: Comparison of different technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acceleration of expiratory flow
Description: Comparison of different technique
Study: NCT03422159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Ascorbic Acid 1.5g IV piggyback every 6 hours for 4 days (or discharge from ICU if prior to 4 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiamine
Description: Thiamine 200mg IV piggyback every 12 hours for 4 days (or discharge from ICU if prior to 4 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone 50mg IV push every 6 hours for 4 days (or discharge from ICU if prior to 4 days).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9%
Description: Placebo Ascorbic Acid 100mL IV piggyback every 6 hours, Placebo Thiamine 50mL IV piggyback every 12 hours, and Placebo Hydrocortisone IV push every 6 hours for 4 days (or discharge from ICU if prior to 4 days).
Study: NCT01744171

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine
Description: Given ID

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00003045

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperthermia
Description: Hyperthermia is delivered by the transrectal ultrasound applicator just prior to XRT, at least one week apart, during the first 4 weeks of XRT. The goal of hyperthermia is CEM T 90 43 greater than or equal to 10 minutes. The maximum applied power duration will be 120 minutes per treatment session

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: XRT
Description: external beam radiation to a dose of 4500 cGy to a small pelvic field, followed by a boost to a reduced volume for an additional 2160 cGy. XRT is given daily, 5 days a week for 180 cGy per day. Total radiation dose=6660cGy
Study: NCT03872258

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Counseling on physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Counseling on physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Program of combined exercise and a Smartband for 6 months.
Study: NCT00829829

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo loading dose followed by placebo injections (2 mL) qw for 16 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rilonacept 80 mg
Description: Rilonacept 160 mg loading dose followed by Rilonacept 80 mg/2 mL injections qw for 16 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rilonacept 160 mg
Description: Rilonacept 320 mg loading dose followed by Rilonacept 160 mg/2 mL injections qw for 16 weeks.
Study: NCT03127813

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Application of continuous positive airway pressure (CPAP)
Description: CPAP will be delivered at 4 different pressure levels (6, 10, 13 and 16cmH2O) in a randomly allocated order

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of continuous positive airway pressure (CPAP)
Description: CPAP will be delivered at 4 different pressure levels (6, 10, 13 and 16cmH2O) in a randomly allocated order

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of continuous positive airway pressure (CPAP)
Description: CPAP will be delivered at 4 different pressure levels (6, 10, 13 and 16cmH2O) in a randomly allocated order
Study: NCT01287975

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occupational Therapy
Description: Use of conventional manual facilitation and function-based training used in conventional occupational therapy training for post-stroke upper limb weakness.~Training is modelled along the neurodevelopmental techniques and will include stretching, tone management, weight bearing exercises, movement facilitation, selfcare training, arm ergometry by arm bicycles and grip strength training.~Training intensity is 1.5 hours for 3 times a week for 6 weeks consecutively.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BCI Haptic Knob
Description: BCI based robotic rehabilitation works by detecting the motor intent of the user from electroencephalogram signals to drive the robotic rehabilitation via Haptic Knob. Training intensity is 1.5 hours for 3 times a week for 6 weeks consecutively.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Haptic Knob
Description: Haptic Knob is an upper limb robot designed for use in robotic-assisted rehabilitation of the stroke wrist and hand. Training intensity is 1.5 hours for 3 times a week for 6 weeks consecutively.
Study: NCT00572975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pentadecanoic acid (PA) and Triheptadecanoin (THA)
Description: Two fats (Pentadecanoic acid and Triheptadecanoin) are administered in a breakfast shake for the purposes of determining malabsorption.~in breakfast shake x1
Study: NCT04805359

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normoxic exercise
Description: Trained on a bicycle ergometer at 60% of maximal work-rate (60%Wmax)for 30 minutes per day, 5 days per week for 6 weeks
Study: NCT00887198

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 placebo tablets per day taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg tablet orally twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: 5 mg tablet orally twice daily.
Study: NCT02648711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRLX101
Description: infusion CRLX101 weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRLX101
Description: infusion CRLX101 weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRLX101
Description: infusion CRLX101 weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: infusion weekly CRLX101 + bevacizumab biweekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: infusion weekly CRLX101 for 3 or every 4 weeks and in combination with bi-weekly mFOLFOX6
Study: NCT04513275

Intervention type: DRUG
Intervention: non-medicine intervention
Description: rating by MCCB only one time
Study: NCT01754532

Intervention type: BIOLOGICAL
Intervention: Hair Sample
Description: Analysis of hair cortisol levels
Study: NCT02048683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short term sedation with sevoflurane in ICU

Intervention type: DRUG
Group type: OTHER
Intervention: Short term sedation with sevoflurane in ICU
Study: NCT02304562

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCB Mesenchymal Stem Cells treatment
Description: reduce skin injury
Study: NCT01165359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITX 5061
Description: For Part A of the study: 150 mg of ITX 5061, once a day for 3 days; 75 mg of ITX 5061, once a day for 3 days; or 25 mg of ITX 5061, once a day for 3 days.~For Part B of the study: 150 mg of ITX 5061, once a day for 14 days; 75 mg of ITX 5061, once a day for 14 days; or 25 mg of ITX 5061, once a day for 14 days.~For Part C of the study: 150 mg of ITX 5061, once a day for 28 days; 75 mg of ITX 5061, once a day for 28 days; or 25 mg of ITX 5061, once a day for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITX 5061
Description: For Part A of the study: 150 mg of ITX 5061, once a day for 3 days; 75 mg of ITX 5061, once a day for 3 days; or 25 mg of ITX 5061, once a day for 3 days.~For Part B of the study: 150 mg of ITX 5061, once a day for 14 days; 75 mg of ITX 5061, once a day for 14 days; or 25 mg of ITX 5061, once a day for 14 days.~For Part C of the study: 150 mg of ITX 5061, once a day for 28 days; 75 mg of ITX 5061, once a day for 28 days; or 25 mg of ITX 5061, once a day for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITX 5061
Description: For Part A of the study: 150 mg of ITX 5061, once a day for 3 days; 75 mg of ITX 5061, once a day for 3 days; or 25 mg of ITX 5061, once a day for 3 days.~For Part B of the study: 150 mg of ITX 5061, once a day for 14 days; 75 mg of ITX 5061, once a day for 14 days; or 25 mg of ITX 5061, once a day for 14 days.~For Part C of the study: 150 mg of ITX 5061, once a day for 28 days; 75 mg of ITX 5061, once a day for 28 days; or 25 mg of ITX 5061, once a day for 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ITX 5061
Description: For Part A of the study: placebo, once a day for 3 days.~For Part B of the study: placebo, once a day for 14 days.~For Part C of the study: placebo, once a day for 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ITX 5061
Description: For Part A of the study: placebo, once a day for 3 days.~For Part B of the study: placebo, once a day for 14 days.~For Part C of the study: placebo, once a day for 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ITX 5061
Description: For Part A of the study: placebo, once a day for 3 days.~For Part B of the study: placebo, once a day for 14 days.~For Part C of the study: placebo, once a day for 28 days.
Study: NCT05684666

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slow Breathing Exercise (SBE)
Description: Slow Breathing Exercise (SBE) delivered in a relaxed supine posture on a couch with keeping the feel flat and knee flexed to 90 degree.~Participants were instructed to make six breaths per minute for 30 minutes per session, twice a week for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slow Breathing Exercise (SBE)
Description: Slow Breathing Exercise (SBE) delivered in a relaxed supine posture on a couch with keeping the feel flat and knee flexed to 90 degree.~Participants were instructed to make six breaths per minute for 30 minutes per session, twice a week for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR) Technique
Description: Progressive Muscle Relaxation (PMR) Technique delivered in a relaxed supine posture on a couch with keeping the feel flat and knee flexed to 90 degree.~Participants were instructed to complete all sixteen steps of PMR technique for 30 minutes per session, twice a week for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR) Technique
Description: Progressive Muscle Relaxation (PMR) Technique delivered in a relaxed supine posture on a couch with keeping the feel flat and knee flexed to 90 degree.~Participants were instructed to complete all sixteen steps of PMR technique for 30 minutes per session, twice a week for 4 weeks.
Study: NCT03330171

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Measles vaccine
Description: All participants will receive measles vaccine at 6 and 12 months of age, according to the South African immunization schedule. All study vaccines are currently licensed in South Africa and will be administered according to their approved dosages, formulations and indications.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Measles vaccine
Description: All participants will receive measles vaccine at 6 and 12 months of age, according to the South African immunization schedule. All study vaccines are currently licensed in South Africa and will be administered according to their approved dosages, formulations and indications.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Hepatitis-A vaccine
Description: Half of the participants (n=135) will receive hepatitis-A vaccine at 18 months of age.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Hepatitis-A vaccine
Description: Half of the participants (n=135) will receive hepatitis-A vaccine at 18 months of age.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Varicella vaccine
Description: Half of the participants (n=135) will receive varicella vaccine at 18 months of age.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Varicella vaccine
Description: Half of the participants (n=135) will receive varicella vaccine at 18 months of age.
Study: NCT01384383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-5885
Description: GS-5885 30 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9451
Description: GS-9451 200 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
Study: NCT04390412

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low Dose Radiotherapy
Description: 0.5 Gy radiation to both lungs in an AP/PA treatment plan